| Nama Pengarang | : | Sofyan H. Nur,Sumardjo,Erna Sri Adiningsih |
| Nama Majalah/Jurnal | : | Warta Lapan |
| Volume / Nomor Edisi | : | XIV-23, APRIL (No. 0) |
| Nomor Halaman | : | 1-7 |
| Abstraksi Narasi | : | - |
| Nama Pengarang | : | Haryanto, Sugeng |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 362-369 |
| Abstraksi Narasi | : | Background. In view of the recent trend toward monotherapy in the treatment of bacterial infection, we evaluate the clinical efficacy and safety of cefepime vs. ceftazidime for the empiric treatment of febrile episodes in neutropenic pediatric cancer patients. Methods. In a single site, open label study, 104 neutropenic pediatric cancer patients [96% with absolute neutrophil count (ANC) of <500 neutrophils/mm3 ] with a median age of 6 years were randomized (1:1) to receive either intravenous cefepime or ceftazidime (50 mg/kg/dose every 8 h; s6 g/day) for empiric treatment of fever (temperature >38.0°C occurring at least twice in 24 h, or single >38.5°C). Febrile episodes were classified as either microbiologically or clinically documented infection or fever of unknown origin. Therapy continued until the ANC was ?1000 neutrophils/mm3 or there was an increasing ANC in low risk patients (maximum duration of treatment, 8 weeks). The primary efficacy endpoints assessed were clinical and microbiologic response to assigned drug therapy. Secondary outcome measures were rate of early discontinuation of study drug and use of concomitant antibiotic therapy to modify initial study drug regimen. Results. Of 68 patients who could be evaluated for efficacy, 74% (26 of 35) of cefepime-treated patients and 70% (23 of 33) of ceftazidime-treated patients responded to treatment. The small number of study patients precluded statistical analysis of results. In a modified intent-to-treat analysis, 59% of the patients treated with cefepime and 47% of ceftazidime-treated patients responded to therapy. Cefepime patients developed fewer new infections than ceftazidime patients (9% vs. 21%, respectively) and early discontinuation of study drug therapy occurred slightly more often in the ceftazidime group. Further, the use of concomitant systemic antimicrobial therapy (mostly vancomycin) occurred less often in the cefepimetrea ted patients, as compared with the ceftazidime group [35% (17 of 49] vs. 44% (24 of 55), respectively]. No deaths or serious adverse events were considered to be related to study therapy. The most frequent adverse event was rash that was moderate in severity, and it occurred equally in both groups. Conclusion. Cefepime appears to be safe and effective compared with ceftazidime for initial empiric therapy of febrile episodes in neutropenic pediatric cancer patients. |
| Nama Pengarang | : | |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 356-361 |
| Abstraksi Narasi | : | Background. Because the introduction of extended spectrum cephalosporins into pediatric practice offers a number of choices for treatment, we review efficacy studies of cefepime monotherapy in the treatment of bacterial meningitis in children. Methods. Two open, randomized, comparative studies assessed the efficacy of cefepime empiric monotherapy in the treatment of bacterial meningitis in 345 pediatric patients. These studies were conducted in Latin America and compared cefepime (50 mg/kg/dose every 8 h) with either cefotaxime (50 mg/kg/dose every 6 h) or ceftriaxone (50 mg/kg/dose every 12 h). Patients 2 months to 14 years old who had clinical signs and symptoms consistent with a central nervous system infection were enrolled. Efficacy was based on clinical and bacteriologic response. Results. Integrated results from the Latin American studies indicated a 75% cure rate with cefepime vs. a 78% cure rate with comparator, among evaluable patients. Overall the rate of treatment failure was 12%. Haemophilus influenzae had the highest bacterial eradication rate (97% overall), and rates were comparable in cefepime and comparator arms. Eradication rates for Neisseria meningitidis were equally high in both treatment arms (95% overall), and the eradication rate for Streptococcus pneumoniae was 92% overall. Of the patients with S. pneumoniae isolated during pretreatment (from either cerebrospinal fluid or blood), 11 (16 isolates in total) had their isolates tested against penicillin and all were susceptible. Presence or absence of seizures, level of consciousness, Glasgow Coma Score and duration of signs and symptoms were strong predictors of outcome. Collectively no specific safety concerns were identified. Conclusion. Cefepime represents an important therapeutic option for the empiric treatment of bacterial meningitis in children, based on the good clinical response and bacteriologic eradication rates observed in this review. |
| Nama Pengarang | : | |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 350-355 |
| Abstraksi Narasi | : | Background. Urinary tract infections (UTis) are common in childhood. They represent a significant proportion (10%) of hospital-acquired infections in children. Bacteria causing UTis in children vary, depending on the setting (community-acquired vs. nosocomial), underlying anatomic anomalies and concurrent medical conditions. Objective. To review published and unpublished clinical studies that have used cefepime for the treatment of UTis in children. Methods and results. In two recent multicenter, randomized trials, cefepime (50 mg/kg/dose every 8 h and every 12 h) was compared with ceftazidime (50 mg/kg/dose every 8 h) for the treatment of serious urinary tract infections including pyelonephritis in children less than 12 years of age. In these studies a favorable clinical and microbiologic response was observed in >95% of cefepime-treated and ceftazidime-treated children assessed at the end of treatment. Conclusions. These results indicate that cefepime represents an important therapeutic option for the treatment of serious UTis in children. |
| Nama Pengarang | : | |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 343-349 |
| Abstraksi Narasi | : | Background. These studies were designed to assess the efficacy and safety of cefepime, a fourth generation cephalosporin, for the treatment of serious infections, including lower respiratory tract infections (LRTI) in children. Methods. Four clinical trials of cefepime for the treatment of serious bacterial infections enrolled 259 children with LRTI. In 3 trials cefepime was compared with ceftazidime (n = 166), cefotaxime (n == 16) or cefuroxime (n = 12). One trial was noncomparative (n = 65). Results. Treatment with cefepime 50 mg/kg/ dose administered every 8 to 12 h produced a satisfactory clinical response (clinical signs of infection resolved or improved with no evidence of recurrent infection at posttreatment followup) in 88 to 100% of patients, comparable with comparator therapy. In children from whom a causative pathogen was identified, bacteriologic eradication was comparable between cefepime and comparator therapy. Cefepime was as safe and well-tolerated as comparator therapy. Few treatment-related clinical or laboratory adverse events were noted and were equivalent to comparator in all studies. Conclusion. Cefepime is as effective, safe and well-tolerated for the empiric treatment of children with LRTI as comparator agents but offers the advantage of an enhanced spectrum of activity for Gram-positive and Gram-negative pathogens compared with second or third generation cephalosporins. |
| Nama Pengarang | : | JEFFREY L. BLUMER, PHD, MD, MICHAEL D. REED, PHARMD AND CATHERINE KNUPP, DVlv1 |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 337-342 |
| Abstraksi Narasi | : | Background. Because determining the pharmacokinetics of drugs used in pediatric patients allows for appropriate dosing and optimal clinical response, we have reviewed the pharmacokinetic data on the use of cefepime in the pediatric population. Methods. Three studies encompassing 88 patients ages 2 months to 16 years examined the pharmacokinetics of cefepime given as a single iv dose, as multiple iv doses and by im administration. In all studies serial blood and urine or cerebrospinal fluid (CSF) samples were collected after a single dose and/or at steady state, defined as after at least 2 days of dosing. Pharmacokinetic parameters were generated from concentration-vs.-time curves and were analyzed using noncompartmental methods. Results. In all studies cefepime exhibited a linear pharmacokinetic profile and concentrations declined proportionally over time. Minimal accumulation was observed after multiple dosing. Pharmacokinetic parameters were similar in all studies and appeared to be dose-independent. Mean (range) parameters observed in this review were: t112 = 1.7 h (1.26 to 1.93); volume of distribution at steady state, 0.37 liter/kg (0.33 to 0.40); total body clearance, 3.1 ml/min/kg (1.43 to 4.01); renal total body clearance, 2.3 ml/min/kg (1.86 to 3.05); absolute bioavailability of cefepime after the im dose, 82.3%; and urinary recovery, 72% (57 to 85%). Penetration into CSF appeared to be good, with CSF concentrations averaging 3.3 to 5. 7 µg/ml 0.5 and 8 h after administration of the dose, respectively. Conclusion. Cefepime displayed a linear pharmacokinetic profile, was well-absorbed via im injection and had adequate penetration into the CSF of patients with bacterial meningitis, compared with other beta-lactams. |
| Nama Pengarang | : | Béatrice Bonga |
| Nama Majalah/Jurnal | : | The pediatric Infectious Disease Journal |
| Volume / Nomor Edisi | : | 20 (No. 3) |
| Nomor Halaman | : | 331-336 |
| Abstraksi Narasi | : | Background. The evolution of the cephalosporin class of antibiotics through modifications of the basic cephem structure has resulted in a new generation with improved antibacterial activity. Cefepime is a prototypic agent of this new class of fourth generation cephalosporins. Objective. To review the microbiologic profile of cefepime. Results. Cefepime, which is a zwitterion, has a net neutral charge that allows it to penetrate the outer membrane of Gram-negative bacteria faster than third generation cephalosporins. It is more stable against beta-lactamases because of the lower affinity of the enzymes for cefepime when compared with third generation cephalosporins. As a result of these structural attributes, cefepime has in vitro activity against pathogens that are prevalent in pediatric infections. This agent offers the advantage of Gram-positive coverage similar to that of cefotaxime and ceftriaxone, as well as good activity against Pseudomonas aeruginosa and many enteric bacilli that are resistant to third generation cephalosporins, including clinical isolates of Enterobacter spp. and Citrobacter freundii. Conclusions. Based on its spectrum of activity cefepime is an option for the treatment of pediatric infections caused by susceptible pathogens. |
| Nama Pengarang | : | Zhenyang Shi,Chung-Yu Hung |
| Nama Majalah/Jurnal | : | Journal of Management Accounting Research |
| Volume / Nomor Edisi | : | 36 (No. 1) |
| Nomor Halaman | : | 173–201 |
| Abstraksi Narasi | : | Although relative performance evaluation (RPE) represents an important compensation practice, selecting a relevant peer firm poses a challenge for compensation committees. We study the implications of a committee`s peer-specific knowledge for the peer group property (i.e., RPE relevance). Committees likely know more about firms within their networks, and such peer-specific knowledge increases with their connections to potential peer firms. Our findings suggest that peer-specific knowledge facilitates not only the inclusion of more relevant peer firms, but also the exclusion of less relevant ones. Moreover, the committees incorporate connected peers` performance information to a greater extent for risk removal. We address identification challenges by including an intensive set of fixed effects to control for characteristics of the focal and the peer firms and by exploiting exogenous changes to the connections between the committees and the peer firms. Our findings suggest that the compensation committee’s peer-specific knowledge facilitates the RPE practice |
| Nama Pengarang | : | Hemmer, Thomas |
| Nama Majalah/Jurnal | : | Journal of Management Accounting Research |
| Volume / Nomor Edisi | : | 36 (No. 1) |
| Nomor Halaman | : | 157–171 |
| Abstraksi Narasi | : | The theoretical prediction of a negative coefficient on positively correlated peer performance underlies much of the empirical literature on relative performance evaluation. This prediction is commonly obtained from a single period model where the variance–covariance matrix of available performance measures is exogenously restricted to be independent of the evaluee`s action. Using the dynamic approach of Holmstrom and Milgrom (1987) € , I study the properties of contracts that optimally condition an agent`s compensation both on his own performance and on how well he fares relative to a peer (group) when these restrictions are not imposed. I show that if the covariance is nonzero, the optimal contract is linear in own and peer performance as well as in their correlation. Significantly, and in line with the preponderance of the empirical evidence, in its simplest and perhaps most reasonable form, the model predicts that the expected coefficient on peer performance is exactly zero |
| Nama Pengarang | : | Maas, Victor S.,Ghita, Razvan S. |
| Nama Majalah/Jurnal | : | Journal of Management Accounting Research |
| Volume / Nomor Edisi | : | 36 (No. 1) |
| Nomor Halaman | : | 139–156 |
| Abstraksi Narasi | : | Span of control and temporal disaggregation of performance reports are two important control system elements that jointly determine the benchmarks that managers have available when evaluating employees` performance. Using an experiment, we investigate whether widening managers` span of control and temporally disaggregating performance reports affect managers` evaluation decisions. We predict and find that managers with a wider span of control evaluate their best performing employees more favorably and their worst performing employees less favorably. We also find that disaggregating performance reports, i.e., providing quarterly performance figures in addition to annual performance figures, has a negative effect on managers` evaluations of their best performing employees, but only when their span of control is wide. We discuss the implications of our findings for management accounting research and practice |